 Legend Biotech Corporation NASDAQ:LEGN told investors that the US regulator, the Food and Drug Administration FDA, had green-lighted its investigational new drug IND application for the treatment of small cell lung cancer SCLC. It means the clinical development can now proceed on LB2102, an investigational, antigen receptor T-cell CAR-T therapy, in a bid to treat adults with extensive stage SCLC. 